Clinical Trial: Deucravacitinib for the Treatment of Palmoplantar Pustulosis
Study Status: Completed
Recruit Status: RECRUITING
Condition: Palmoplantar Pustulosis
Study Type: INTERVENTIONAL
Official Title: Deucravacitinib for the Treatment of Palmoplantar Pustulosis
Brief Summary:
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP.All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
Read more